Adagio - International Biopharmaceutical Industry

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Subsection - Oncology

Essential DMPK Strategies for IND Success

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

news

Adagio plans comeback for COVID drug, but is it too late?

Dive Brief: Adagio Therapeutics said it will ask the Food and Drug Administration for emergency authorization of its COVID-19 drug after announcing Wednesday that ...

1 April 2022 news Adagio | adintrevimab

Continue Reading →

news

Adagio pledges to press forward with COVID drug as CEO to resign

Dive Brief: Adagio Therapeutics CEO Tillman Gerngross has agreed "in principle" to resign as head of the COVID-19 drug developer amid confusion over whether its mo...

24 February 2022 news Adagio | Adimab

Continue Reading →

news

Adagio, after bold promises, says antibody drug won’t work well against omicron

The findings are a huge disappointment for Adagio, which billed ADG20 as a weapon that could neutralize a wide range of variants and help with future outbreaks. The c...